These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 30755497

  • 1. Nuclear factor erythroid 2-related factors 1 and 2 are able to define the worst prognosis group among high-risk diffuse large B cell lymphomas treated with R-CHOEP.
    Kari E, Teppo HR, Haapasaari KM, Kuusisto MEL, Lemma A, Karihtala P, Pirinen R, Soini Y, Jantunen E, Turpeenniemi-Hujanen T, Kuittinen O.
    J Clin Pathol; 2019 Apr; 72(4):316-321. PubMed ID: 30755497
    [Abstract] [Full Text] [Related]

  • 2. Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy.
    Shin HC, Seo J, Kang BW, Moon JH, Chae YS, Lee SJ, Lee YJ, Han S, Seo SK, Kim JG, Sohn SK, Park TI.
    Korean J Intern Med; 2014 Nov; 29(6):785-92. PubMed ID: 25378977
    [Abstract] [Full Text] [Related]

  • 3. The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.
    Tadic L, Marjanovic G, Macukanovic-Golubovic L, Krstic M, Jevtovic-Stoimenov T, Kostov M, Smelcerovic Z, Stojanovic M.
    J BUON; 2016 Nov; 21(5):1259-1267. PubMed ID: 27837631
    [Abstract] [Full Text] [Related]

  • 4. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.
    Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, Glass B, Scott DW, Gascoyne RD, Connors JM, Ziepert M, Pfreundschuh M, Loeffler M, Savage KJ.
    J Clin Oncol; 2016 Sep 10; 34(26):3150-6. PubMed ID: 27382100
    [Abstract] [Full Text] [Related]

  • 5. A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution.
    Huang JJ, Xia Y, Wang Y, Liu PP, Bi XW, Sun P, Lin TY, Jiang WQ, Li ZM.
    Oncotarget; 2016 Jul 05; 7(27):41242-41250. PubMed ID: 27183909
    [Abstract] [Full Text] [Related]

  • 6. CD30 expression and prognostic significance in R-EPOCH-treated patients with diffuse large B-cell lymphoma.
    Xu J, Oki Y, Saksena A, Desai P, Lin P, Tang G, Yin CC, You MJ, Thakral B, Medeiros LJ, Li S.
    Hum Pathol; 2017 Feb 05; 60():160-166. PubMed ID: 27816715
    [Abstract] [Full Text] [Related]

  • 7. Reduced-dose EPOCH-R chemotherapy for elderly patients with advanced stage diffuse large B cell lymphoma.
    Zhang WH, Li GY, Ma YJ, Li ZC, Zhu Y, Chang J, Hao SG, Tao R.
    Ann Hematol; 2018 Oct 05; 97(10):1809-1816. PubMed ID: 29754271
    [Abstract] [Full Text] [Related]

  • 8. Thalidomide enhanced the efficacy of CHOP chemotherapy in the treatment of diffuse large B cell lymphoma: A phase II study.
    Ji D, Li Q, Cao J, Guo Y, Lv F, Liu X, Wang B, Wang L, Luo Z, Chang J, Wu X, Hong X.
    Oncotarget; 2016 May 31; 7(22):33331-9. PubMed ID: 27129176
    [Abstract] [Full Text] [Related]

  • 9. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A, Martelli M, Angelucci E, Brusamolino E, Evangelista A, Carella AM, Stelitano C, Rossi G, Balzarotti M, Merli F, Gaidano G, Pavone V, Rigacci L, Zaja F, D'Arco A, Cascavilla N, Russo E, Castellino A, Gotti M, Congiu AG, Cabras MG, Tucci A, Agostinelli C, Ciccone G, Pileri SA, Vitolo U.
    Lancet Oncol; 2017 Aug 31; 18(8):1076-1088. PubMed ID: 28668386
    [Abstract] [Full Text] [Related]

  • 10. Cell of origin predicts outcome to treatment with etoposide-containing chemotherapy in young patients with high-risk diffuse large B-cell lymphoma.
    Gang AO, Pedersen MØ, Knudsen H, Lauritzen AF, Pedersen M, Nielsen SL, Brown P, Høgdall E, Klausen TW, Nørgaard P.
    Leuk Lymphoma; 2015 Jul 31; 56(7):2039-46. PubMed ID: 25379621
    [Abstract] [Full Text] [Related]

  • 11. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.
    Liew PL, Hsu CS, Liu WM, Lee YC, Lee YC, Chen CL.
    Int J Clin Exp Pathol; 2015 Jul 31; 8(5):5642-9. PubMed ID: 26191276
    [Abstract] [Full Text] [Related]

  • 12. Lack of prognostic value of MMP-9 expression and immunohistochemically defined germinal center phenotype in patients with diffuse large B-cell lymphoma treated with modern chemotherapy with or without CD20 antibody.
    Kyllönen H, Pasanen AK, Kuittinen O, Haapasaari KM, Turpeenniemi-Hujanen T.
    Leuk Lymphoma; 2009 Aug 31; 50(8):1301-7. PubMed ID: 19811332
    [Abstract] [Full Text] [Related]

  • 13. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM, Ziepert M, Horn H, Scott DW, Barth TFE, Bernd HW, Feller AC, Klapper W, Szczepanowski M, Hummel M, Stein H, Lenze D, Hansmann ML, Hartmann S, Möller P, Cogliatti S, Lenz G, Trümper L, Löffler M, Schmitz N, Pfreundschuh M, Rosenwald A, Ott G, German High-Grade Lymphoma Study Group.
    J Clin Oncol; 2017 Aug 01; 35(22):2515-2526. PubMed ID: 28525305
    [Abstract] [Full Text] [Related]

  • 14. Thioredoxin-1 as a biological predictive marker for selecting diffuse large B-cell lymphoma patients for etoposide-containing treatment.
    Kari EJM, Kuusisto MEL, Honkavaara P, Hakalahti A, Haapasaari KM, Bloigu R, Karihtala P, Teppo HR, Pirinen R, Turpeenniemi-Hujanen T, Kuittinen O.
    Eur J Haematol; 2020 Aug 01; 105(2):156-163. PubMed ID: 32248578
    [Abstract] [Full Text] [Related]

  • 15. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
    Fridrik MA, Jaeger U, Petzer A, Willenbacher W, Keil F, Lang A, Andel J, Burgstaller S, Krieger O, Oberaigner W, Sihorsch K, Greil R.
    Eur J Cancer; 2016 May 01; 58():112-21. PubMed ID: 26990931
    [Abstract] [Full Text] [Related]

  • 16. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
    Jovanovic MP, Mihaljevic B, Jakovic L, Martinovic VC, Fekete MD, Andjelic B, Antic D, Bogdanovic A, Boricic N, Terzic T, Jelicic J, Milenkovic S.
    J BUON; 2015 May 01; 20(3):820-8. PubMed ID: 26214636
    [Abstract] [Full Text] [Related]

  • 17. Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.
    Pedersen MØ, Gang AO, Brown P, Pedersen M, Knudsen H, Nielsen SL, Poulsen T, Wirenfeldt Klausen T, Høgdall E, Nørgaard P.
    PLoS One; 2017 May 01; 12(10):e0186983. PubMed ID: 29088292
    [Abstract] [Full Text] [Related]

  • 18. Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial.
    Friedrichs B, Nickelsen M, Ziepert M, Altmann B, Haenel M, Viardot A, Schmidt C, Ruebe C, Loeffler M, Pfreundschuh M, Rosenwald A, Glass B, Lenz G, Schmitz N, German high-grade lymphoma Study Group.
    Br J Haematol; 2019 Mar 01; 184(5):760-768. PubMed ID: 30520013
    [Abstract] [Full Text] [Related]

  • 19. Hyperfibrinogenemia is a poor prognostic factor in diffuse large B cell lymphoma.
    Niu JY, Tian T, Zhu HY, Liang JH, Wu W, Cao L, Lu RN, Wang L, Li JY, Xu W.
    Ann Hematol; 2018 Oct 01; 97(10):1841-1849. PubMed ID: 29860562
    [Abstract] [Full Text] [Related]

  • 20. An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era.
    Sun F, Zhu J, Lu S, Zhen Z, Wang J, Huang J, Ding Z, Zeng M, Sun X.
    BMC Cancer; 2018 Jan 02; 18(1):5. PubMed ID: 29291712
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.